Drug Launch Strategy

Key Influencing Factors for a Successful Drug Launch in Emerging Pharma

Q: What makes the pre-launch window so decisive for a drug's commercial success?

The roughly 24 months before approval is when the highest-leverage decisions get locked in, including target patient population, value proposition, evidence strategy, pricing, channel design, and field design. Because a brand's long-term trajectory is largely established within the first six months on the market, the preparation completed during the pre-launch period determines much of its future commercial performance.

Q: What is the crawl-walk-run model for launch readiness?

The crawl-walk-run model is a phased approach that builds launch capabilities in proportion to risk. The Crawl phase, spanning pre-clinical through Phase II, focuses on establishing a lean data foundation and clinical data management. The Walk phase, covering Phase III and pre-launch activities, adds market access, pricing, and forecasting capabilities. The Run phase, which begins at launch and extends post-launch, scales these capabilities into a full commercial engine. Each phase builds on the previous one without requiring a complete rebuild.

Q: What are the five factors that determine whether an emerging pharma launch succeeds?

The five factors are market access and pricing strategy, regulatory and compliance readiness, stakeholder engagement, patient pool identification for rare disease and novel therapies, and data insights accelerated by GenAI. These factors are interdependent and should advance in parallel during the pre-launch period, as weaknesses in one area can negatively affect performance in the others.

Q: How is launching a rare disease therapy different from a general-medicine launch?

Rare disease patient populations are typically small, heterogeneous, and geographically dispersed, making diagnosis and patient recruitment more challenging. Diagnostic delays can span years, and clinical trial data is often limited by small sample sizes. Advanced patient-finding techniques and look-alike modeling using EMR, claims, and genomic data help expand the addressable patient pool and accelerate diagnosis in ways that are generally not required for traditional general-medicine launches.

Q: What should an emerging pharma team actually do in the next 24 months before approval?

Emerging pharma teams should begin launch planning during clinical development rather than waiting until trials conclude. They should establish a lean data foundation early and scale it as the asset matures. Payers and key opinion leaders should be engaged 18 to 24 months before approval while evidence strategies can still be influenced. Teams should also manage market access, compliance, stakeholder engagement, patient identification, and data strategy as one connected launch agenda rather than separate workstreams.

Download White Paper

From clinical development to commercialization, pre-launch preparedness decides the outcome

Large pharmaceutical companies are narrowing their pipelines to fewer, higher-value programs, and emerging pharma organizations are taking on more of the work advancing novel therapies, especially in rare diseases. Innovation alone does not guarantee commercial success. A drug's lifetime value is decided not at launch, but in the quarters of preparation that precede it.

Why the Launch Window Is Unforgiving

66% of launches miss analyst expectations.
70% of a brand's trajectory is set within the first six months on market.
75% of peak sales potential is determined within year one.
65%+ of new active substances globally now originate from emerging pharma (2020–2024).

A Crawl-Walk-Run Operating Model

Pre-launch readiness works best as a phased journey, not a final sprint before approval. Capabilities mature as the asset advances, so resource-constrained organizations build only what the molecule needs, when it needs it, without rebuilding later.

Crawl (Pre-Clinical to Phase II): lean data and infrastructure foundation, clinical data management, RWE/HEOR evidence base, patient journey mapping.
Walk (Phase III and Pre-Launch): market access and pricing model, forecast and market sizing, field sizing and targeting, omnichannel and CRM build.
Run (Launch and Post-Launch): brand uptake and pull-through, channel ROI and IC administration, performance dashboards, patient look-alike scaling.

Five Factors That Determine Launch Success

Market access and pricing strategy: Affordability and fragmented reimbursement pathways shape access. Early payer engagement, typically 18 to 12 months before launch, aligns trial endpoints with reimbursement criteria.
Regulatory and compliance readiness: Regulatory frameworks vary widely by region. Automated dossier generation and AI-enabled compliance monitoring accelerate NDA/BLA submissions and PDUFA timelines.
Stakeholder engagement: Physicians are skeptical of novel therapies without real-world evidence. Early, continuous KOL engagement and personalized HCP outreach build the trust that drives adoption.
Patient pool identification: Rare disease populations are small, dispersed, and hard to diagnose. Advanced patient finding and look-alike modeling expand the addressable pool.
Data insights and GenAI acceleration: Fragmented clinical, commercial, and regulatory data limits insight. A unified platform paired with GenAI turns raw data into usable intelligence across the lifecycle.

The Operating Model That Actually Works

Emerging pharma rarely has the luxury of large, standing commercial organizations. The model that works is lean and modular, built on three capabilities under one governed program: launch consulting and program management, a commercial data foundation, and commercial insights and analytics. Speed comes from packaged, reusable capability. Discipline comes from a governed, milestone-driven plan that begins well before approval.